Prevents deep vein thrombosis (DVT). ANDA 91316, held by Dr Reddys Labs Ltd. Fondaparinux Sodium.
As of Nov 16, 2026, ANDA 91316 (Fondaparinux Sodium), held by Dr Reddys Labs Ltd, was first approved by FDA on Jul 11, 2011, with 2 approved supplements and 0 published complete response letters.
Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. ( 1.2, 1.3 ) 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 11, 2011 | Original application | Approved |
| Fondaparinux Sodium2.5MG/0.5ML (2.5MG/0.5ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium5MG/0.4ML (5MG/0.4ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium7.5MG/0.6ML (7.5MG/0.6ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Fondaparinux Sodium10MG/0.8ML (10MG/0.8ML) · solution;subcutaneous | Fondaparinux Sodium | Rx |
| Feb 18, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 19, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 11, 2011 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters